Skip to content
Search

Capital at risk. Past performance is not a reliable indicator of current or future results and should not be the sole factor of consideration when selecting a product or strategy.

The listed funds are not an exhaustive list of funds available. Visit www.funds.troweprice.com to see the full range of funds offered by T. Rowe Price, including those that consider environmental and social characteristics as part of their investment process.  For up to date information regarding any T. Rowe Price fund's investment strategy, please see the relevant fund KID and prospectus. 

OEIC
US Large Cap Growth Equity Fund
Seeking to identify investments with the potential to deliver double-digit earnings growth.
ISIN GB00BD5FHW12
View more information on risks
FACTSHEET
KIID

Overview
Strategy
Fund Summary
Deliver long-term returns from attractive U.S. companies with high-quality earnings streams, strong free cash flow growth and shareholder-oriented management.
31-Mar-2022 - Taymour Tamaddon, Portfolio Manager,

We took advantage of indiscriminate selling in the growth space to add exposure to names that we believe offer aggressive growth potential or that have a proven history as high-quality compounders. We moved to reduce our bets in stocks with emerging headwinds that could suppress multiples in the near term.

Information Technology

Disruptive business models and technologies within the sector continue to present compelling investment opportunities. Secular demand for public cloud computing services continues to be a growth driver. We also continue to favor companies driven by the convergence of communications and computing, including internet software companies, and those that will benefit from broad global tailwinds in digital payments.

  • We purchased shares of enterprise software company Atlassian. We like the company's strong management team, impressive product portfolio, and large opportunity set. We also appreciate the long growth runway Atlassian has as it benefits from emerging software development trends, cloud migration, and a low-cost flywheel sales model. In our view, the stock carries significant upside potential given the recent pullback in growth-oriented names.
  • We bought shares of Fiserv on relative weakness. The stock continued to suffer from negative sentiment regarding the potential disruption of the fintech space by new competitors. We are optimistic about Fiserv's growth potential as mobile banking penetration continues to increase and as the company's point-of-sale platform, Clover, expands as a share of revenue.
  • We sold shares of software-as-a-service leader Splunk. While we still see Splunk as a category-defining company in the machine data collection and analysis space, we recognize the potential for a protracted executive search and transition timeline following the CEO's unexpected departure. The company is also in the midst of a challenging transition from on-premise to cloud-based services.

Communication Services

Within the sector, we are focused on companies that are benefiting from the shift of advertising spending to digital and social media channels. We also favor wireless communication services firms with strong company-specific growth prospects and competitive advantages or differentiated business models.

  • We sold shares of Meta Platforms in light of emerging long-term risks to the business, including rising competitive threats and shifting consumer social media behavior. The company also continues to face privacy headwinds from app tracking transparency initiatives that have hurt industrywide advertising revenues. While we have confidence in the company's mitigation efforts, Meta's advanced, hyper-optimized advertising solutions mean that the company faces a deeper reset than others as it designs workarounds to restore the signal loss. Meta is one of two leading platforms that we expect to benefit from a multi-decade transition from offline to online advertising, and it offers investors a rare combination of scale, growth, and profitability at an attractive valuation with multiple catalysts that include a collection of under-monetized surfaces and social commerce initiatives.

Health Care

We remain focused on finding opportunities to take advantage of lasting trends such as managed care industry consolidation, innovations in medical equipment, and robotic technology. In therapeutics, our emphasis is on select companies that have strong fundamentals and the potential to bring additional new drugs to market in areas with large, unmet clinical needs.

  • We sold shares of hospital operator HCA Healthcare in order to fund purchases of attractively valued names elsewhere in the portfolio. In our view, the stock's risk/reward profile is less favorable coming off of an exceptional 2021 as coronavirus tailwinds begin to fade. Over the long term, we continue to have a favorable view of HCA due to its excellent management team, strategic long-term capital deployment strategy, and attractive geographic mix.

Past performance is not a reliable indicator of future performance.

The Funds are sub-funds of the T. Rowe Price Funds OEIC, an investment company with variable capital incorporated in England and Wales which is registered with the UK Financial Conduct Authority and which qualifies as an undertaking for collective investment in transferable securities (“UCITS”). Full details of the objectives, investment policies and risks are located in the prospectus which is available with the key investor information documents in English and in an official language of the jurisdictions in which the Funds are registered for public sale, together with the articles of incorporation and the annual and semi-annual reports (together "Fund Documents"). Any decision to invest should be made on the basis of the Fund Documents which are available free of charge from the local representative, local information/paying agent or from authorised distributors and via www.troweprice.com.

Hedged share classes (denoted by 'h') utilise investment techniques to mitigate currency risk between the underlying investment currency(ies) of the fund and the currency of the hedged share class.  The costs of doing so will be borne by the share class and there is no guarantee that such hedging will be effective.

Before deciding to invest in the fund, you should read the offering document/prospectus (including its investment objectives, policies and any risk warnings) which are available and may be obtained from any appointed distributors.

The specific securities identified and described in this website do not represent all of the securities purchased, sold, or recommended for the sub-fund and no assumptions should be made that the securities identified and discussed were or will be profitable.


A full list of the currently issued Share Classes including Distributing, Hedged, and Accumulating Categories may be obtained, free of charge and upon request, from the registered office of the Company.  

Benchmark: Investors may use the benchmark to compare the fund’s performance. The benchmark has been selected because it is similar to the investment universe used by the investment manager and therefore acts as an appropriate comparator. The investment manager is not constrained by any country, sector and/or individual security weightings relative to the benchmark and has complete freedom to invest in securities that do not form part of the benchmark.

IA Sector: Many UK funds are grouped into sectors by the Investment Association (the “IA”) (the trade body that represents UK investment managers), to help investors to compare funds with broadly similar characteristics. Investors may compare the fund against the performance of the Europe Excluding UK sector. This sector represents the average performance of certain funds that invest at least 80% of their assets in European shares and exclude UK securities. It can therefore serve as a method of comparing the fund’s performance with other funds that have broadly similar characteristics. The fund is not constrained to or managed in line with this sector. Source for IA Sector Data: © Morningstar. All Rights Reserved.

Disclosures on Vendor Indices can be found here.